Pityriasis Rosea After Pfizer-BioNTech Covid-19 Vaccine: A Case Report
Turkish Journal of Internal Medicine · 2022
DOI: 10.46310/tjim.1072232 ↗Kurz gefasst
Fallbericht in der Zeitschrift Turkish Journal of Internal Medicine, 2022. Verfasst von Şeyma Handan AKYÖN und 1 weiteren Autor:innen. Die Arbeit nennt 17 Literaturangaben.
Abstract (Originalsprache)
After the pandemic started, vaccines against SARS-CoV-2 were developed and applied in a short time. Later, various side effects were reported during the use of these vaccines. Among the skin side effects, besides local skin reactions at the injection site, urticaria, maculopapular rash and pityriasis rosea-like reactions were observed. We presented a female case who developed pityriasis rosea after administering the 3rd dose of the Pfizer-BioNTech COVID-19 vaccine.
Zitieren
APA
AKYÖN, Ş. H., & GENÇ, Y. (2022). Pityriasis Rosea After Pfizer-BioNTech Covid-19 Vaccine: A Case Report. Turkish Journal of Internal Medicine. https://doi.org/10.46310/tjim.1072232
Vancouver
AKYÖN ŞH, GENÇ Y. Pityriasis Rosea After Pfizer-BioNTech Covid-19 Vaccine: A Case Report. Turkish Journal of Internal Medicine. 2022. doi:10.46310/tjim.1072232
BibTeX
@article{AKYN2022,
author = {AKYÖN, Şeyma Handan and GENÇ, Yeşer},
title = {Pityriasis Rosea After Pfizer-BioNTech Covid-19 Vaccine: A Case Report},
journal = {Turkish Journal of Internal Medicine},
year = {2022},
doi = {10.46310/tjim.1072232}
}
EUVIMED